Principal Financial Group Inc. Sells 362,215 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Principal Financial Group Inc. decreased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 91.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,439 shares of the company’s stock after selling 362,215 shares during the quarter. Principal Financial Group Inc.’s holdings in Recursion Pharmaceuticals were worth $266,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in RXRX. Mubadala Investment Co PJSC bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth about $128,041,000. Gladstone Institutional Advisory LLC purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $133,000. Capstone Investment Advisors LLC purchased a new position in Recursion Pharmaceuticals in the first quarter worth about $161,000. Norges Bank purchased a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $34,825,000. Finally, UBS Group AG lifted its stake in Recursion Pharmaceuticals by 101.9% during the 4th quarter. UBS Group AG now owns 691,911 shares of the company’s stock valued at $6,822,000 after acquiring an additional 349,232 shares during the period. Institutional investors own 89.06% of the company’s stock.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00. Following the completion of the sale, the chief financial officer now owns 1,377,756 shares of the company’s stock, valued at $8,500,754.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00. Following the transaction, the chief financial officer now owns 1,377,756 shares of the company’s stock, valued at approximately $8,500,754.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total value of $120,800.00. Following the sale, the chief executive officer now owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 231,682 shares of company stock worth $1,663,867. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $6.57 on Friday. The firm’s fifty day moving average is $7.23 and its 200 day moving average is $8.55. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -4.11 and a beta of 0.82. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same quarter in the previous year, the company posted ($0.38) earnings per share. The business’s revenue for the quarter was up 30.9% on a year-over-year basis. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RXRX. Needham & Company LLC reduced their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Jefferies Financial Group cut their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Finally, KeyCorp cut their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.